Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

RGEN is acquiring BioLife for $1.5B to expand its cell therapy capabilities, adding biopreservation products. Management expects incremental revenue and EPS benefits from the deal. The move is positioned as supportive for RGEN’s growth trajectory in cell therapies, though the article provides no specific financial impact figures beyond the $1.5B price.

Analysis

RGEN is acquiring BioLife for $1.5B to expand its cell therapy capabilities, adding biopreservation products. Management expects incremental revenue and EPS benefits from the deal. The move is positioned as supportive for RGEN’s growth trajectory in cell therapies, though the article provides no specific financial impact figures beyond the $1.5B price.